This message contains images. If you don't see images, click here to view.
Click here to advertise in this news brief.

  Mobile version   RSS   Subscribe   Unsubscribe   Archive   Media Kit Jul. 26, 2012

   Home   Mission/Vision    Membership    Corporate Membership    CME/CEU    JMCM    Contact Us

Click Here to view the Journal of Managed Care Medicine

Online CME/CEU Programs
Multiple Myeloma: An Update on Diagnostic and Treatment Strategies

Advanced Treatment of Osteoporosis in Postmenopausal Women

Decreasing the Cost Burden of Fibromyalgia with Early Diagnosis and Management

Announcing the NAMCP Medical Directors Lung Cancer Resource Center. Click here to visit the website.

Be sure to check out the study results of Verinata's Non-Invasive Prenatal Technology. Click here to view the press release.

Click here to check out the "Latest in Clinical Nutrition" DVD available for purchase now!

Fall Managed Care Forum
November 8-9
Bellagio Hotel



Contest for sequencing genomes has 1st entry
The New York Times    Share    Share on FacebookTwitterShare on LinkedinE-mail article
The first contestant has entered the competition for the X Prize in genomics, which will offer $10 million to a team that can accurately and completely sequence the genomes of 100 people in 30 days at a cost below $1,000 per genome. The competitor is Ion Torrent, a sequencing machine manufacturer owned by Life Technologies. More

Alzheimer's genetic drug fails in 1 study, 2nd continues
The Associated Press via USA Today    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Pfizer has said that a closely watched experimental Alzheimer's drug failed to slow the disease in one late-stage study, but the drug maker said it will continue to study the drug's effect on a different group of patients. Pfizer, testing bapineuzumab with partner Johnson & Johnson, said the injected drug didn't slow mental or functional decline in patients with mild or moderate Alzheimer's disease. The study included patients who carry a gene called ApoE4, which gives people a higher risk of developing the memory-robbing disorder. More

Now Hiring! Disability Examination Providers

The VA Locum Tenens Program seeks physicians and psychologists to perform disability examinations for general medicine and mental health conditions. Physicians will provide compensation and pension examinations for Veterans who file for disability claims. This position requires extensive travel around the country. Compensation package includes salary and full travel. Send your CV to or contact us at 1-866-664-1030.

DNA facility inks deal to open New York headquarters
WNYC    Share    Share on FacebookTwitterShare on LinkedinE-mail article
A research center that will be the largest DNA sequencing and analytics facility in North America is moving into New York's Lower Manhattan, officials announced. The New York Genome Center — a collaboration of 11 hospitals that serve about 10 million patients — was expected to open in 2012, but the project faced delays as the group searched for a location that could accommodate its machinery and space requirements. More

 Biotech/Diagnostics/Personalized Medicine

FDA balances costs, patient safety in biologics, personalized medicine
Forbes    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Rather than treating the disease's consequences, biologics work by blocking diseases early in their development, in the immune system, and can be individually tailored to a the person taking the medicine — a revolutionary turn along the windy road toward our personalized medicine future. So what are the issues? Expense and patient safety. More


Your patient's blood doesn't tell you that they will get tired walking the dog. Or that they've had heartburn for the past 2 weeks. But it can tell you whether or not obstructive CAD is what's causing their symptoms. You may not need to go deeper than the blood to know what's happening. MORE

Targeting technology improves outcomes for atrial fibrillation
Medical Xpress    Share    Share on FacebookTwitterShare on LinkedinE-mail article
In a landmark study of atrial fibrillation, researchers report having found for the first time that these irregular heart rhythms are caused by small electrical sources within the heart, in the form of electrical spinning tops or focal beats. More


Nursing@Georgetown is a Master’s in Nursing program delivered online by Georgetown University’s renowned School of Nursing & Health Studies.
Our activities touch many lives
AstraZeneca is a global, innovation-driven, integrated biopharmaceutical company. We discover, develop, manufacture and market prescription medicines for cancer, cardiovascular, gastrointestinal and infection. MORE

 Regenerative Medicine

Stem cells show promise as heart failure treatment
HealthDay News via U.S. News & World Report    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Scientists who used modified stem cells to rejuvenate damaged and aged heart cells from elderly heart failure patients say their research could one day lead to new treatments for the illness. Stem cells taken from the patients were modified with a protein called PIM-1, which promotes cells survival and growth. The modified stem cells helped the signaling and structure of the patients' heart cells by boosting the activity of an enzyme called telomerase, which elongates telomeres. More

Researchers find driver of breast cancer stem cell metastasis
Bioscience Technology    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Researchers have found that a cancer gene linked to aggressive spread of the disease promotes breast cancer stem cells. The finding implies a new way to target the behavior of these lethal cells. The finding involves the cancer gene RhoC, which has previously been shown to promote metastasis of many types of cancer. RhoC levels increase as breast cancer progresses and high levels of RhoC are associated with worse patient survival. More

 Emerging Medical Technologies

The iRobot doc will see you now
Mashable    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Some people complain their doctors are too stiff, lack warmth and are too robotic. But calling such doctors "robots" may be a disservice to RP-Vita — the latest telepresence, healthcare bot from InTouch Health and iRobot. RP-VITA — Remote Presence Virtual + Independent Telemedicine Assistant — is a remote-controlled telepresence robot. It may be controlled via joystick, but RP-Vita does have some awareness of its environment. More

Electronic glove helps improve spinal cord injury victims' motor skills
Medgadget    Share    Share on FacebookTwitterShare on LinkedinE-mail article
A research team from Georgia Tech has been working on a rehab glove that is already showing effectiveness for people with limited hand motor skills and proprioception due to spinal injury. The electronic Mobile Music Touch glove works with a piano and vibrates individual fingers to point to which keys should be pressed. More

 Managed Healthcare News

Study: 1 in 10 US employers to drop health coverage
The Wall Street Journal    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Around one in 10 employers in the U.S. plans to drop health coverage for workers in the next few years as the bulk of the federal healthcare law begins, and more indicated they may do so over time, according to a study by consulting company Deloitte. More

'Child life specialists' help sick children be children
Kaiser Health News    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Kelly Schraf is a child life specialist, a type of healthcare provider whose job is to help sick children and their families navigate difficult medical situations emotionally and psychologically while in the hospital. They do it largely through play — the basis of how a child learns and grows. There are about 4,000 child life specialists in the country. Most of them work in acute units with the very sickest children. More

 FDA: New Treatments and Technology

FDA staff say Roche drug helped diabetics see
Reuters    Share    Share on FacebookTwitterShare on LinkedinE-mail article
U.S. drug reviewers said Roche Holding AG's eye drug Lucentis appeared to help diabetic patients with a vision-robbing eye condition, and raised few major issues about the drug's safety. Food & Drug Administration staff reviewed Lucentis ahead of an advisory panel of outside experts, which is set to vote on whether to recommend approval of an expanded use of the drug, which is administered monthly by injection. More

COPD drug wins FDA approval
MedPage Today    Share    Share on FacebookTwitterShare on LinkedinE-mail article
The FDA has approved aclidinium bromide for long-term treatment of bronchospasm associated with chronic obstructive pulmonary disease, the agency announced. Aclidinium bromide, distributed by Forest Laboratories subsidiary Forest Pharmaceuticals, is a dry powder inhaler used twice daily. It is a newer type of anticholinergic known as a long-acting M3 muscarinic antagonist. More

"COPD, or chronic obstructive pulmonary disease, is among the most common lung diseases and can be linked to exposure to certain gases or fumes in the workplace, and heavy amounts of secondhand smoke and pollution."

Genomics Biotech and Emerging Medical Technologies Institute eBrief
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Christine Kraly, Content Editor, 469.420.2685   
Contribute news

This edition of the Genomics Biotech and Emerging Medical Technologies Institute eBrief was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!
Recent issues
July 19, 2012
July 12, 2012
July 5, 2012
June 28, 2012

7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063